DAX20.642 -5,0%ESt504.878 -4,6%Top 10 Crypto11,23 +2,3%Dow38.315 -5,5%Nas15.588 -5,8%Bitcoin72.557 -4,8%Euro1,0961 ±0,0%Öl66,06 -5,4%Gold3.038 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 Amazon 906866 Allianz 840400 Apple 865985 Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 Novo Nordisk A3EU6F Microsoft 870747 Berkshire Hathaway A0YJQ2 BASF BASF11 Volkswagen (VW) vz. 766403 Lufthansa 823212 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Zölle: China schlägt zurück -- DAX geht massiv tiefer ins Wochenende -- Wall Street stürzt letztlich ab -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus
Top News
Gaspreis, Goldpreis, Ölpreis & Co aktuell Gaspreis, Goldpreis, Ölpreis & Co aktuell
Nach Zollbeben: Proteste gegen Trump und Musk Nach Zollbeben: Proteste gegen Trump und Musk
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Bis zu 3,05 % Zinsen: Jetzt die besten Tagesgeld-Angebote checken

Carisma Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,1759 EUR +0,0095 EUR +5,71 %
STU
0,1970 USD +0,0059 USD +3,09 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.7,30 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DZG2

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS14216R1014

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCARM

Carisma Therapeutics Aktien News

DatumMeistgelesen
PR NewswireCarisma Therapeutics Provides Corporate Updates
PR NewswireCarisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PR NewswireCarisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Wer­bungCarisma Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireCarisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
PR NewswireCarisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR NewswireCarisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
PR NewswireCarisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
PR NewswireCarisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireCarisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
PR NewswireCarisma Therapeutics Announces Changes to its Board of Directors
PR NewswireCarisma Therapeutics Announces Upcoming Presentations at SITC 2024
PR NewswireCarisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
PR NewswireCarisma Therapeutics to Present at Upcoming Conferences
PR NewswireCarisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireCarisma Therapeutics Announces Expansion of Its Scientific Advisory Board
PR NewswireCarisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
PR NewswireCarisma Therapeutics Announces Changes to its Board of Directors
PR NewswireCarisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
PR NewswireCarisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
PR NewswireCarisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
PR NewswireCarisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
PR NewswireCarisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR NewswireCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
PR NewswireCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireCarisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
PR NewswireCarisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
PR NewswireCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
PR NewswireCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
PR NewswireCarisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
PR NewswireCarisma Therapeutics to Present at Upcoming Conferences
PR NewswireCarisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PR NewswireCarisma Therapeutics Announces Changes to its Board of Directors
PR NewswireCarisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
PR NewswireCarisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
PR NewswireCarisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireFirst In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
PR NewswireCarisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
PR NewswireCarisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
PR NewswireCarisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireCarisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
Wer­bung

Carisma Therapeutics News

Carisma Therapeutics News: auf dieser Seite finden Sie alle Carisma Therapeutics News und Nachrichten zur Carisma Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Carisma Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Carisma Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.